drugset / Trial / NCT06827899
Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML
Phase 2
Recruiting
66 enrolled
The First Affiliated Hospital of Xiamen University
Fujian Cancer Hospital · collabFujian Provincial Hospital · collabHuizhou Municipal Central Hospital · collabJieyang People's Hospital · collabZhangzhou Affiliated Hospital of Fujian Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
A multicenter, prospective, single-arm clinical study of veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG) in the treatment of elderly untreated acute myeloid leukemia (AML)
Timeline
- Start
- 2022-07-01
- Primary completion
- 2026-06-30
- Completion
- 2027-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | — |
| Subject | Decitabine | Small molecule | — | — |
| Subject | chidaniline | Unknown | — | — |
| Subject | veneclax | Unknown | — | — |